Related references
Note: Only part of the references are listed.A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)
Christopher Wynne et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program
Kristin Karlsdottir et al.
FRONTIERS IN MEDICINE (2022)
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study
Steven R. Feldman et al.
BIODRUGS (2021)
Overview of Humira® Biosimilars: Current European Landscape and Future Implications
Jill Coghlan et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2021)
Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs
Francesca Civoli et al.
AAPS JOURNAL (2020)
Update on the diagnosis and management of early rheumatoid arthritis
Peter C. Taylor
CLINICAL MEDICINE (2020)
A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects
Jim Bush et al.
BMC PHARMACOLOGY & TOXICOLOGY (2019)
Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects
Donghoon Shin et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis
Peter Nash et al.
RHEUMATOLOGY AND THERAPY (2016)
Systematic Verification of Bioanalytical Similarity Between a Biosimilar and a Reference Biotherapeutic: Committee Recommendations for the Development and Validation of a Single Ligand-Binding Assay to Support Pharmacokinetic Assessments
Joseph C. Marini et al.
AAPS JOURNAL (2014)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)